{"article_title": "Court Decision Could Allow Novartis To Sell Copy of Amgen\u2019s Neupogen", "article_keywords": ["sell", "selling", "court", "way", "federal", "decision", "amgens", "drug", "novartis", "version", "allow", "zarxio", "appeals", "copy", "neupogen"], "article_url": "http://www.wsj.com/articles/court-decision-could-allow-novartis-to-sell-copy-of-amgens-neupogen-1441223368", "article_text": "A federal appeals court in Washington denied Amgen Inc.\u2019s request for a temporary injunction to block Novartis AG from selling a copycat version of the blockbuster drug Neupogen in the U.S.\n\nThe decision by the U.S. Court of Appeals for the Federal Circuit could clear the way for Novartis to begin selling Zarxio, a knockoff version of Neupogen that was approved by the U.S. Food and Drug Administration in March. The U.S. market...", "article_metadata": {"article.template": "snippet", "article.created": "2015-09-02T19:49:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "A federal appeals court in Washington denied Amgen Inc.\u2019s request for a temporary injunction to block Novartis AG from selling a copycat version of the blockbuster drug Neupogen in the U.S.", "creator": "@Loftus", "image": {"src": "https://si.wsj.net/public/resources/images/BN-JX184_0818am_G_20150818131805.jpg", "alt": "Court decision could allow Novartis to sell copy of Amgen\u2019s Neupogen", "identifier": "https://si.wsj.net/public/resources/images/BN-JX184_0818am_D_20150818131805.jpg"}, "title": "Court Decision Could Allow Novartis To Sell Copy of Amgen\u2019s Neupogen", "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10934841746633634231704581209051190611110&headline=Court%20decision%20could%20allow%20Novartis%20to%20sell%20copy%20of%20Amgen%u2019s%20Neupogen&weburl=http://www.wsj.com/articles/SB10934841746633634231704581209051190611110"}}, "page.site.product": "WSJ", "keywords": "amgen,biosimliars,chemotherapy drugs,neupogen,novartis,zarxio,Amgen,AMGN,Novartis,NOVN.VX,U.S. Food and Drug Administration,corporate crime,legal action,regulation,government policy,new products,services,new product approvals,corporate,industrial news,biotechnology,pharmaceuticals,health care,life sciences,biopharmaceuticals", "news_keywords": "amgen,biosimliars,chemotherapy drugs,neupogen,novartis,zarxio,Amgen,AMGN,Novartis,NOVN.VX", "article.headline": "Court decision could allow Novartis to sell copy of Amgen\u2019s Neupogen", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-JX184_0818am_E_20150818131805.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-JX184_0818am_D_20150818131805.jpg"}}, "description": "A federal appeals court in Washington denied Amgen Inc.\u2019s request for a temporary injunction to block Novartis AG from selling a copycat version of the blockbuster drug Neupogen in the U.S.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10934841746633634231704581209051190611110&headline=Court%20decision%20could%20allow%20Novartis%20to%20sell%20copy%20of%20Amgen%u2019s%20Neupogen&weburl=http://www.wsj.com/articles/SB10934841746633634231704581209051190611110", "user.type": "nonsubscriber", "article.page": "Business", "page.content.format": "responsive", "article.summary": "A federal appeals court in Washington denied Amgen Inc.\u2019s request for a temporary injunction to block Novartis AG from selling a copycat version of the blockbuster drug Neupogen in the U.S.", "page.site": "wsj", "testkeys": "C", "article.published": "2015-09-02T19:52:00.000Z", "dj.asn": "i-f264", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"publisher": "https://www.facebook.com/wsj", "embed_count": 1, "image_count": 1, "word_count": 362, "internal_link_count": 5}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "A federal appeals court in Washington denied Amgen Inc.\u2019s request for a temporary injunction to block Novartis AG from selling a copycat version of the blockbuster drug Neupogen in the U.S.", "title": "Court Decision Could Allow Novartis To Sell Copy of Amgen\u2019s Neupogen", "url": "http://www.wsj.com/articles/court-decision-could-allow-novartis-to-sell-copy-of-amgens-neupogen-1441223368", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-JX184_0818am_G_20150818131805.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Peter Loftus", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Court Decision Could Allow Novartis To Sell Copy of Amgen\u2019s Neupogen", "article.type": "Business", "article.id": "SB10934841746633634231704581209051190611110", "user.exp": "default", "article.updated": "2015-09-02T19:52:00.000Z"}, "_id": "\"57477af46914bd0286fe43ea\"", "article_summary": "A federal appeals court in Washington denied Amgen Inc.\u2019s request for a temporary injunction to block Novartis AG from selling a copycat version of the blockbuster drug Neupogen in the U.S.\nThe decision by the U.S. Court of Appeals for the Federal Circuit could clear the way for Novartis to begin selling Zarxio, a knockoff version of Neupogen that was approved by the U.S. Food and Drug Administration in March.\nThe U.S. market..."}